Brief: Kezar Life Sciences Announces Positive IDMC Safety Review Of Portola Trial Of Zetomipzomib In Patients With Autoimmune Hepatitis And Provides Palizade Update

Kezar Life Sciences

17/10/2024 13:37

Oct 17 (Reuters) - Kezar Life Sciences Inc  KZR.O :
    * KEZAR LIFE SCIENCES ANNOUNCES POSITIVE IDMC SAFETY REVIEW
OF
PORTOLA TRIAL OF ZETOMIPZOMIB IN PATIENTS WITH AUTOIMMUNE
HEPATITIS AND PROVIDES PALIZADE UPDATE
    * KEZAR LIFE SCIENCES INC - PALIZADE PHASE 2B CLINICAL TRIAL
IN
PATIENTS WITH ACTIVE LUPUS NEPHRITIS (LN) WILL BE DISCONTINUED
    * KEZAR LIFE SCIENCES INC - PORTOLA TRIAL TO CONTINUE
WITHOUT
MODIFICATION, TOPLINE DATA IN H1 2025

Source text for Eikon:  ID:nBw9Z61sTa 
Further company coverage:  KZR.O 

 ((Reuters.Briefs@thomsonreuters.com;))